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Summary
DNA replication must be tightly regulated to ensure that
the genome is accurately duplicated during each cell
cycle. When these regulatory mechanisms fail, replicative
stress and DNA damage ensue. Activated oncogenes pro-
mote replicative stress, inducing a DNA damage response
(DDR) early in tumorigenesis. Senescence or apoptosis
result, forming a barrier against tumour progression. This
may provide a selective pressure for acquisition of muta-
tions in the DDR pathway during tumorigenesis. Despite
its potential importance in early cancer development, the
precise nature of oncogene-induced replicative stress
remains poorly understood. Here, we review our current
understanding of replication initiation and its regulation,
describe mechanisms by which activated oncogenes
might interfere with these processes and discuss how
replicative stress might contribute to the genomic insta-
bility seen in cancers.
Introduction
Genomic instability occurs in almost all human cancers, but
whether it is an active force during cancer evolution or
simply a consequence of tumour progression has been a
subject of debate [1,2]. Evidence now suggests that DNA
damage occurs early in tumorigenesis in a wide array of
cancers [3,4]. This is before signs of telomere attrition or
hypoxia, which have long been known to cause DNA dam-
age [4–8]. Instead it has been proposed that activated onco-
genes, selected for their ability to promote proliferation,
cause replicative stress. This replicative stress, character-
ised by increased numbers of stalled and collapsed re-
plication forks, accounts for early DNA damage [3,4]. In
precancerous lesions, this DNA damage triggers a strong
DNA damage response (DDR), which induces senescence
or apoptosis, forming a barrier against tumour progression
[9,10]. Only when further genetic or epigenetic changes
down-regulate the DDR, usually via the tumour suppressor
p53 pathway, is tumorigenesis able to proceed. Patterns of
DNA damage and oncogenic mutations in mouse cancer
models and human tumours support the oncogene-induced
replicative stress model over other models of oncogene-
induced senescence, such as that mediated by the tumour
suppressor ARF (reviewed in [11,12]). Therefore in the early
stages of tumorigenesis, replicative stress appears to be
responsible for generating genomic instability and a DDR
to limit cancer development, and this in turn provides the
selective pressure for acquisition of further mutations that
promote tumour progression.
Given its apparent key role in the early stages of cancer
development, surprisingly little is known about the nature
of oncogene-induced replicative stress. It is possible it isCancer Research UK London Research Institute, Clare Hall
Laboratories, South Mimms, Herts, EN6 3LD, UK.
*E-mail: John.Diffley@cancer.org.ukcaused by replication of a damaged DNA template, for
example caused by reactive oxygen species [13,14], but
oncogene-induced replicative stress in cultured cells is inde-
pendent of oxidative stress [3]. Instead recent data suggest
that activated oncogenes might have a more direct effect
upon the regulation of DNA replication, and this will be the
focus of our review. We begin by summarising our current
understanding of replication initiation and its regulation,
focussing on metazoans, before describing potential mech-
anisms for oncogene-induced replicative stress and how
they trigger DNA damage. Finally we discuss how replicative
stress might promote the types of genomic instability
commonly seen in cancers and how the causes of replicative
stress might change as cancer evolves.
DNA Replication Initiation and Its Regulation
The eukaryotic cell cycle is driven by periodic oscillations in
theactivity of cyclin-dependentkinase (CDK), due toperiodic,
antiphase oscillations of cyclin synthesis and the anaphase-
promoting complex/cyclosome (APC/C), which targets
cyclins for degradation. APC/C activity is high andCDK activ-
ity low from late mitosis through G1 phase. G1 cyclins (cyclin
D in metazoans), which accumulate in response to mitogenic
signalling, trigger the phosphorylation and inactivation of the
retinoblastoma protein (RB), a cell cycle inhibitor. This re-
leases the transcriptional activator E2F (Figure 1A; reviewed
in [15]), which promotes expression of the G1/S and S phase
cyclins (cyclins E andA, which bind to CDK2 in G1/S, inmeta-
zoans) along with various other proteins required for S phase
progression, including the replication factors Cdc6 andCdt1,
discussed below. High CDK activity drives entry into S phase
and inhibits APC/C activity. High CDK activity is maintained
through G2 phase and mitosis. Ultimately, mitotic cyclin–
CDK (cyclin B/Cdk1 inmetazoans) promotes its own inactiva-
tion by reactivating theAPC/C,which triggersmitotic exit and
the start of the low CDK period of the next cell cycle.
Replication must be strictly coordinated with the cell cycle
to ensure faithful duplication of the genome. The first step in
replication initiation is the assembly of prereplicative com-
plexes (pre-RCs) at replication origins, a process known as
licensing. During licensing, the core replicative helicase
component, the hexameric minichromosome maintenance
2-7 (MCM) complex, is loaded around double-stranded
DNA as an inactive double hexamer (Figure 1B) [16–18].
Loading MCM requires several other pre-RC factors: the
six subunit origin recognition complex (ORC; subunits
Orc1-6), Cdc6 and Cdt1. At the G1/S transition, two kinases,
CDK and Dbf4-dependent kinase (DDK), activate the MCM
helicase, which involves the recruitment of Cdc45 and the
heterotetrameric GINS complex to form the CMG complex
[19–21]. The conversion of pre-RCs into bidirectional repli-
somes requires a host of other factors, including Sld2
(RecQL4 in metazoans), Sld3 (Treslin/TICRR in metazoans),
Sld7 (currently no clear orthologue identified, but MTBP
may perform a similar role in metazoans [22]), Mcm10 and
Dpb11 (TopBP1 in metazoans) (Figure 1B).
Preventing Re-Replication
To ensure replication happens once and only once during
the cell cycle, the two steps of replication initiation, origin
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Figure 1. The G1/S transition and replication
initiation.
(A) During G1, mitogenic stimulation triggers
Ras-dependent signalling, which activates
cyclin D transcription and cyclin D/CDK4
assembly. Cyclin D/CDK4 phosphorylates
and inactivates RB, which releases E2F from
inhibition. E2F then promotes expression of
various genes required for S phase entry.
Cyclin E is an E2F target, which completes
phosphorylation and inactivation of RB,
thereby providing positive feedback to drive
cells into S phase. The RB–E2F pathway
becomes deregulated by various oncogenes
(in green) and tumour suppressor genes (in
red), to promote S phase entry and cell prolif-
eration. (B) Replication initiation occurs in two
temporally separated steps, origin licensing
and origin firing. Origin licensing occurs from
late mitosis to the end of G1, when CDK
activity is low. ORC, Cdc6 andCdt1 cooperate
to load the MCM2-7 complex onto chromatin
as an inactive head-to-head double hexamer
around double-stranded DNA. At the G1/S
transition, origin firing begins, driven by the
action of two kinases, CDK andDDK. The con-
version of an inactive double hexamer into two
functional replisomes involves several firing
factors, including Sld2, Sld3, Sld7, Mcm10,
Dpb11 and DNA polymerase ε, which together
aid the recruitment of Cdc45 and GINS to
form the CMG complex, which stimulates the
helicase activity of the MCM2-7 complex. Ori-
gins do not fire synchronously during S phase
and the time of origin firing is associated with
the time of association of firing factors.
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tion is coordinated by changes in CDK activity. High CDK
activity triggers origin firing and marks the start of S phase.
CDKs also inhibit assembly of pre-RCs so once an origin
has fired it cannot be relicensed until the cell has exited the
subsequent mitosis, ensuring origins fire just once in each
cell cycle. CDK phosphorylates and inhibits various pre-RC
components: in the budding yeast Saccharomyces cerevi-
siae, CDK phosphorylation causes ubiquitin-mediated pro-
teolysis of Cdc6 by CRL1Cdc4 [23,24], nuclear export of the
MCM complex [25,26] and inactivation of Orc2 and Orc6
[27–30]. In mammalian cells, CDK phosphorylation of pre-
RC components can also play a direct role in blocking
licensing (Figure 2). Phosphorylated Cdt1 and Orc1 are
targeted for ubiquitin-mediated degradation by CRL1Skp2
[31–33] and phosphorylation and ubiquitylation of Orc1 can
cause its nuclear export during S and G2 phase [34]. Orc2
chromatin binding is inhibited upon CDK phosphorylation
[32,35]. Cdc6 is also phosphorylated by CDK during S phase
but how this inhibits pre-RC assembly is still unclear. Ectopic
overexpressed Cdc6 is exported from the nucleus during S
phase [36,37], and consistent with this a pool of endogenous
Cdc6 has been shown to be exported [38]. However, the
chromatin-bound fraction of endogenous Cdc6 remains
unaltered throughout S phase [38–40].
There are two further mechanisms to inhibit origin
licensing outside of G1 phase in metazoans, and both act
on the pre-RC factor Cdt1 (Figure 2; reviewed in [41]). First,
geminin, an APC/C target that is present from S through
to M phase, binds Cdt1 and inhibits its chromatin bind-
ing [42–46]. Second, chromatin-bound Cdt1 is subjectedto replication-coupled PCNA-mediated ubiquitination and
proteolysis by the CRL4Cdt2 pathway [47–49]. Because
APC/C activity and the onset of DNA replication are both
regulated by CDK, these two mechanisms are indirectly
CDK-dependent.
The Licensing Checkpoint
In yeast, if pre-RC assembly is partially inhibited during G1
phase, cells enter S phase with reduced numbers of origins
and this causes genomic instability, as discussed below
[50–53]. However, if origin licensing during G1 phase is
inhibited in human cells by expression of non-degradable
geminin [54] or depletion of pre-RC factors [55–58], cells
arrest in G1 phase. How pre-RC assembly is monitored by
this ‘licensing checkpoint’ and how this signal is transduced
to downstream targets is still unclear. However, it is clear
that licensing inhibition results in a reduction in cyclin
E/CDK2 activity and concomitant Rb hypophosphorylation
[56–58], suggesting that the checkpoint works by maintain-
ing repression of E2F to prevent S phase entry. This has
been linked to an increase in levels of the CDK inhibitors
p27 and p21 [57], an independent reduction in cyclin D
expression [56] and a loss of CDK2-activating phosphoryla-
tion and nuclear accumulation [58]. Maintenance of the
licensing checkpoint also requires p53, since p53 depletion
from licensing-deficient cells overcomes G1 arrest and
allows progression into S phase [58].
Temporal Program of Replication
Origins do not all fire simultaneously at the onset of S phase,
but follow a predetermined temporal pattern [59,60]. In
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Figure 2. Prevention of re-replication in metazoans.
CDKs inhibit origin licensing by phosphorylating several members of
the pre-RC. Phosphorylation of Cdc6 may cause its nuclear export;
phosphorylation of Orc2 inhibits its chromatin binding; phosphoryla-
tion of Orc1 and Cdt1 targets them for ubiquitin-mediated degradation
by CRL1Skp2, and phosphorylation and ubiquitylation of Orc1
also causes nuclear export. Additionally, Cdt1 is degraded by the
CRL4Cdt2 pathway via replication-coupled PCNA-mediated ubiquitina-
tion and is sequestered by geminin, preventing its chromatin binding.
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Sld3, Sld2, Sld7, Dpb11 and Dbf4 [61,62], are recruited prefer-
entially to early-firing origins during G1 and only to late-firing
origins during S phase [63,64], resulting in temporally ordered
origin firing (discussed in [65]). In human cells, at least Cdc45
also appears to be limiting for replication [66].
Replicative Stress Following Inappropriate Origin
Licensing or Firing
Together, the regulatory pathways described ensure that the
genome is accurately duplicated in each cell cycle. If any of
these pathways are disrupted, origin usage during S phase
will be altered. In this section we summarise evidence indi-
cating that replicative stress and genome instability can be
caused by reduced origin usage, increased origin usage or
re-use of origins in a single cell cycle. We also discuss
each of these with respect to oncogenesis.
Origin Under-Usage
Reducing the levels of pre-RC factors or increasing the levels
of licensing inhibitors can result in fewer MCM complexes
being loaded onto DNA and fewer origins firing in S phase.
In budding yeast, which lacks a licensing checkpoint,
increasing G1 CDK activity by overexpressing a G1 cyclin
or deleting a CDK inhibitor inhibits the assembly of pre-
RCs and causes cells to enter S phasewith reduced numbers
of active origins [52,53]. The licensing checkpoint prevents S
phase entry in normal mammalian cells with reduced origin
licensing. In cancer cells, however, the licensing checkpoint
is often compromised, presumably because the p53 and Rb/
E2F pathways that mediate the checkpoint are frequently
deregulated, either bymutation or through oncogenic signal-
ling (reviewed in [15]). Thus, when licensing is inhibited,
cancer cells enter S phase with reduced numbers of func-
tional replication origins [54,55,58].
In yeast, inhibition of origin licensing causes genomic
instability; entering S phase with too few active origins
causes double-strand breaks (DSBs), increased recombina-
tion and gross chromosomal rearrangements [50–53]. In hu-
man cancer cells lacking a functional licensing checkpoint,
licensing inhibition causes DNA damage, an abortive S
phase and apoptosis [54,55,58].
Despite the fact that MCMs are loaded onto DNA in 3–10-
fold excess over those used for normal origin firing [67–69],
reducing licensing still affects genome stability. This is
because these excess or ‘dormant’ origins [70] are required
to act as back-ups in times of replication fork stalling and
collapse during S phase, since origins cannot be licensed
at this stage (reviewed in [71,72]). There is evidence that
extra origins can be selected for activation in G1 in response
to replicative stress in the previous S phase, which may be
important in cells experiencing chronic replicative stress
[73]. Nonetheless, it is possible to deplete MCMs to such a
level that normal replication is not perturbed, and a licensing
checkpoint is not activated in normal mammalian cells, but
the number of dormant origins is reduced. These cells are
hypersensitive to exogenous forms of replicative stress,
which increase the frequency of fork stalling, resulting in
DNA lesions and checkpoint activation [70,74–76]. They
also tend to show higher levels of spontaneous DNA damage
presumably because there is more fork stalling even in an
unchallenged S phase [75–78].
Thus, entering S phase with a reduced number of potential
origins promotes DNA damage and genome instability inyeast and human cells. The mechanism by which reduced
licensing generates damage is unknown. One possibility is
that each fork has to cover a greater distance, which might
increase the chance of replication fork stalling. Once a fork
stalls, there will also be fewer dormant origins available for
rescue, and therefore the stalled fork may persist, increasing
the likelihood of the fork collapsing and DSBs developing.
The reduction in origin usage may also increase the prob-
ability that cells will enter mitosis with incompletely
replicated DNA. The presence of replication intermediates
will prevent efficient chromosome segregation and cause
chromosome breakage during mitosis [79]. Mitotic abnor-
malities, including lagging chromosomes, anaphase bridges
and acentric chromosomes as well asmicronuclei have been
shown to develop in response to licensing inhibition, through
CDK misregulation or MCM depletion [52,76,80].
Mouse models of licensing deficiency have been devel-
oped where the numbers of licensed origins are reduced
but the animals are still viable. Both the Mcm4 chaosmutant
and the Mcm2IRES-CreERT2 mouse are cancer-prone, devel-
oping a variety of tumours dependent on genetic back-
ground [77,81,82]. Tumorigenesis is accelerated in a
p53-deficient background suggesting that the DDR acts as
an anti-cancer barrier in response to replicative stress [77].
This suggests, at least in mouse models, that licensing inhi-
bition could be a driving force behind tumorigenesis.
In most human cancers, the pathways that control CDK2
activation during G1 become deregulated (Figure 1A;
reviewed in [83,84]). In addition to driving uncontrolled prolif-
eration, this might also limit the low CDK ‘window’ during G1
phase, resulting in reduced levels of origin licensing, similar
to the situation in yeast [52,53]. Cyclin E, a G1/S cyclin and
positive regulator of CDK2, is frequently deregulated in
malignancies, associated with gene amplification or more
commonly with disruption of the pathways that control its
periodicity [85,86]. Overexpression of cyclin E in human
cells causes genomic instability and specifically inhibits
MCM chromatin binding during G1, causing a reduction in
origin firing during S phase [87,88]. Longer replication
tracks and increased fork stalling are seen upon cyclin E
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[3,89]. Although these experiments were performed on
cancer cells, which presumably lack a functional licensing
checkpoint, one might predict that overexpression of cyclin
E would override the checkpoint and promote S phase entry
with insufficiently licensed origins even in cells with an other-
wise functional licensing checkpoint. Consistent with this,
overexpression of various oncogenes seems to compromise
the licensing checkpoint; HPV E7 sensitises cells to MCM
depletion [56], a KRAS mutant sensitises cells to Cdc6
depletion [90] and Myc overexpression sensitises cells to
Orc1 depletion [91]. It will be interesting to investigate
whether these and other oncogenes also indirectly inhibit
licensing, by deregulating CDK activity in order to promote
cell cycle entry.
Origin Over-Usage
Increasing the number of active origins in S phase or disturb-
ing the temporal program of origin activation can also pro-
mote genomic instability. In budding yeast, increasing
levels of the normally limiting firing factors causes increased
firing of replication origins in early S phase, and this is asso-
ciated with DNA damage and reduced viability [61,62,92].
Similarly, increasing the level of Cdc45 in Xenopus causes
increased early origin firing and a DDR [93]. While transient
overexpression of Cdc45 in human cells causes increased
origin firing, constitutive overexpression results in reduced
proliferative capacity, suggesting that increased early origin
firing is detrimental for cells [66].
Experiments aimed to directly manipulate the replication
timing program in a variety of organisms suggest that origin
over-usage can promote genomic instability. Increased
origin activity may exhaust substrates required for replica-
tion, such as deoxynucleoside triphosphates (dNTPs;
discussed in [94]) and RPA [95]. This would presumably
result in reduced fork speed and an increased chance of
fork stalling. Asymmetric forks, which are thought to be an
indicator of fork stalling, are seen when origin activity is
directly increased in yeast and DNA damage can be rescued
by increasing dNTP levels in vivo [61]. RPA is not only limiting
for replication but also has a protective role in preventing
DNA damage; RPA coats both newly generated single-
stranded DNA (ssDNA) at ongoing replication forks and
stretches of ssDNA persisting at stalled forks, shielding
it from nucleases. Excessive origin firing can deplete RPA
and therefore increase DSB formation at unprotected
ssDNA [95].
Increased numbers of replicons may clash with other pro-
cesses that occur on DNA, such as transcription. Transcrip-
tion occurs during S phase but, like replication, is temporally
and spatially regulated in such a manner that it is generally
separated from replication territories [96,97]. Even so, there
are situations, even in an unperturbed S phase, where repli-
cation and transcription machineries encounter one another
and this causes replication forks to stall until the block is
bypassed (reviewed in [98]). An increase in the number of
forks due to origin over-usage or disruption of the temporal
regulation of replication may increase the chance of replica-
tion–transcription collisions and thus increase the chance of
fork collapse and DNA damage.
Overexpression of several oncogenes, including cyclin E,
HPV E6 and E7, Myc and Ras, reduces inter-origin distance
in human cells, indicating that, at least in localised regions,
origin firing is increased [10,89,99,100]. Each of theseoncogenes also causes a hyperproliferative phenotype by
accelerating the G1/S transition (Figure 1A), suggestive of
deregulatedCDK activation. In fact, inXenopus egg extracts,
simply increasing CDK activity causes late origins to fire
early [101], so this seems a likely explanation for increased
origin firing in response to oncogenic activity.
The oncogene Myc may influence origin activation more
directly, since it binds DNA close to replication origins,
interacts with members of the pre-RC and colocalises with
replication foci in early S phase [99]. Myc is known to antag-
onise the CDK inhibitor p27 [102] and therefore has been
suggested to lower the threshold of CDK required locally at
replication origins [93]. In Xenopus egg extracts, adding
p27 to levels that would normally inhibit replication rescues
over-initiation following excess Myc addition, suggesting
that p27 counteracts the effects of Myc [93].
Alternatively, activation of supernumerary replication
origins by oncogenes may be a secondary consequence of
some other form of replication stress. As discussed above,
dormant origins can be activated by factors which slow or
stall replication forks, thus reducing inter-origin distance
[74,75]. This might go some way to explaining why cyclin E
overexpression appears to have dual effects on replication
initiation, both reducing licensing and increasing origin firing,
if these effects occur sequentially. Alternatively these con-
flicting results might be explained by the way in which cyclin
E is upregulated in different systems. Cyclin E expression is
normally restricted to S phase but if overexpression causes it
to become deregulated relative to the cell cycle, this would
limit the low CDK period in G1 and inhibit licensing. In
contrast, if cyclin E overexpression causes higher levels
specifically in S phase, increased origin activity would ensue.
Oncogene-induced replicative stress shows many of
the characteristics of stress induced by increased origin
firing. For example, replicative stress induced by some
oncogenes can be rescued by addition of exogenous nucle-
osides, suggesting nucleotide levels may have become
depleted, perhaps as a consequence of origin over-usage
[10,89,99,100]. In addition cyclin E overexpression has
been shown to specifically increase the extent of replica-
tion–transcription interference, and cyclin E-induced replica-
tive stress can be limited using transcription inhibitors [100].
Origin Re-Usage
If inappropriate re-licensing of replication origins occurs
from S to mitosis, when CDK levels are high, origins may
fire more than once within a single cell cycle and this can
result in re-replication of DNA.
In eukaryotes, there are several overlapping mechanisms
acting to prevent re-licensing, as already discussed. The
redundancy in the system suggests that disrupting one
such pathway should not result in re-replication. This is
certainly true in budding yeast; only when all three CDK
regulatory pathways are inhibited, by expression of pre-RC
mutants refractory to CDK regulation, is significant re-repli-
cation observed [27]. Similarly, in mammalian cells, overex-
pression of the CDK targets Cdc6 or ORC does not cause
substantial re-replication [34,36,103,104]. The third target
of regulation in metazoans, Cdt1, is more tightly regulated,
being inhibited by CDK, geminin and CRL4-dependent
degradation, suggesting its deregulation might be more
harmful to the cell [41]. Consistent with this, in Xenopus
egg extracts, Drosophila and mammalian cells, excess
Cdt1 alone can induce re-replication, indicating that the
Special Issue
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to block re-replication when Cdt1 is overexpressed
[43,46,104–112]. Interestingly, this response to Cdt1 overex-
pression is seen in cancer cells but not in normal primary or
immortalised human cells [103,104,107]. In fact in normal
mammalian cells, like yeast, it seems that extensive re-repli-
cation only occurs when all three inhibitory targets of the pre-
RC are overexpressed [113]. The propensity of cancer cells
to re-replicate upon deregulation of Cdt1 suggests that
some of the normal, redundant regulation of licensing has
been compromised. This may be due, in part, to the fact
that many pre-RC factors are already overexpressed in
cancer (reviewed in [114] and discussed below).
Re-replication can cause cell death and genome insta-
bility [28,46,115]. In yeast, Xenopus egg extracts and
human cells, re-replication causes checkpoint activation
associated with the appearance of ssDNA and DSBs
[43,46,104,106,107,116–120]. In addition, there is evidence
to suggest that normal but not cancer cells possess a sepa-
rate checkpoint that limits re-replication in its very early
stages [104,107]. This ATR-mediated checkpoint may detect
ssDNA that accumulates early on during re-replication due to
extensive DNA unwinding by the replicative helicase at
re-licensed origins, uncoupled from DNA synthesis, perhaps
due to an imbalance in levels of polymerases and replication
origins [107].
Precisely how re-replication causes DNA damage and
activates checkpoints is still unclear, but several mecha-
nisms have been proposed. If re-initiation of replication is
infrequent, the resulting replication forks will be relatively
isolated and therefore will have to travel some distance
before meeting another fork, which increases the chance of
fork stalling (discussed in [121]). Since the fork is unlikely
to be rescued by a neighbouring fork, the stalled fork will
persist, increasing the likelihood of fork collapse and DNA
breakage. If re-initiation from any origin is a frequent event,
there is the chance that replication forks will end up ‘chasing’
one another along DNA, potentially causing head-to-tail
collisions and irreversible fork stalling, as has been seen in
Xenopus egg extracts supplemented with excess Cdt1
[117]. Deregulated origin firing can also rapidly generate
ssDNA gaps due to fork collapse, which act as obstacles
for re-replicating forks and induce further fork stalling,
collapse and DSBs [122].
Origin re-firing may increase the number of replication
forks during S phase, in a similar manner to origin over-
usage. In turn it might also cause replication elongation
factors to become depleted or clashes with transcription.
Alternatively, origin re-firing and the associated replicative
stress may inhibit origin firing via activation of DNA damage
checkpoints [72], which might lead to an overall reduction in
origin firing, and the potential problems associated with this
(see above).
It has been proposed that re-replication has some role to
play during cancer progression. Licensing factors are
frequently upregulated in cancer cells [100,103,119,123–
125]. This is not simply due to increased cell proliferation
since it does not correlate with other proliferation markers,
such as Ki-67, suggesting the increased levels may cause
misregulation of the replication licensing system. The pre-
RC factors Cdt1 and Cdc6 can both act as oncogenes;
transgenic Cdt1 mice and mice injected with Cdt1- or
Cdc6-overexpressing cells develop tumours [119,126,127].
Many pre-RC factor encoding genes are E2F targets [128]and, since the Rb/E2F pathway is frequently deregulated
through oncogenic signalling, this might explain why overex-
pression of licensing proteins is so common. In fact, Cdc6
has been shown to be directly upregulated in response to
Ras, cyclin E and Mos overexpression [3,10,129]. Moreover,
cyclin E and Ras can cause re-replication in human cells
when over-expressed [3,10].
Replicative Stress Promotes Genomic Instability
Several mechanisms have been proposed to explain how
replicative stress leads to genome instability. Common
fragile sites (CFSs) are segments of the genome prone to
breakage when cells are exposed to replicative stress, and
are already expressed (i.e. broken) in precancerous lesions
when the DDR is still active, suggesting DNA damage at
these sites is one of the earliest steps in tumorigenesis
[3,4]. These sites tend to occur in late-replicating, AT-rich
regions and are often associated with large genes.
Accordingly, some CFSs are particularly susceptible to repli-
cation–transcription interference, since replication and
transcription often occur simultaneously on long open
reading frames [130]. Activated oncogenes that increase
the frequency of origin firing or alter the replication timing
program could thereby increase the chance of collisions
and therefore the chance of fork stalling and collapse.
In contrast, for many CFSs the instability of the site does
not correlate with its expression level [131]. Instead, it
appears these sites are intrinsically difficult to replicate.
Many CFSs are prone to breakage under reduced licensing
conditions, for example after MCM depletion [132]. This is
because CFSs appear to be either origin-deficient [133] or
activate all dormant origins under unchallenged conditions
due to AT-rich sequences that promote fork stalling [132].
Recently other genomic regions have been found to be
particularly sensitive to replicative stress; these have been
termed early-replicating fragile sites (ERFSs) and are located
in highly transcribed, repetitive and CpG-rich regions. Here,
replication–transcription collisions certainly appear to play a
role in instability. Similarly to CFSs, these sites have also
been shown to be sensitive to oncogene activation [134].
As well as preferentially targeting CFSs and ERFSs, all
types of replicative stress discussed in this review can
induce genome-wide fork stalling. This can result in
immediate fork collapse and breakage during S phase but
many replication intermediates, particularly at CFSs, persist
into mitosis [135,136], presumably because they replicate
late and remain shielded by RPA [95]. Frequently the sister
chromatids remain interlinked due to under-replication or
unresolved replication structures [135] and these are
resolved in mitosis by structure-specific nucleases that
cleave the DNA to prevent formation of anaphase bridges,
generating DSBs [137,138]. In addition, condensation of
chromosomes harbouring unresolved intermediates may
also be particularly prone to breakage [136].
The DSBs generated as a result of replicative stress are
precursors for genomic instability; in fission yeast, expres-
sion of an inducible replication fork barrier resulted in fork
stalling and site-specific gross chromosomal rearrange-
ments [139]. In sporadic cancers, chromosomal instability
(CIN) is the most common form of instability, characterised
by changes in chromosomal structure and number (reviewed
in [12]). These structural changes, including translocations,
amplifications and deletions, can be explained by error-
prone repair of DSBs. Non-homologous end joining and
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Figure 3. Copy number increase of replication
factors in cancer.
(A) Frequency (as percent) of amplification
of various genes involved in initiating
DNA replication. Data were taken from the
Memorial Sloan-Kettering Cancer Center’s
cBioPortal web site (http://www.cbioportal.
org/public-portal/), which collates data from
original sources [144,151–155]. (B) Diagram
of human chromosome 8 showing the posi-
tions of MTBP, MYC and RECQL4.
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R440microhomology-mediated end joining generate structural
rearrangements and loss of material, as well as commonly
observed microhomology at breakpoints. Replicative repair
pathways, known to occur in yeast, have been proposed to
explain the complex structural rearrangements and genomic
duplications prevalent in cancer [140,141]. This involves a
stalled replication fork continuing replication on a new tem-
plate mediated by microhomology. The low processivity of
the polymerase causes frequent fork stalling and potentially
many rounds of template switching. Recently, break-
induced replication has been shown to occur in human cells
and to be responsible for a significant proportion of genomic
amplifications in cyclin E-overexpressing cell lines [142].
Although the choice of error-prone pathways might seem
surprising, it is possible the homologous recombination
machinery becomes overwhelmed by large numbers of
DSBs, as is likely the case under conditions of replicative
stress (reviewed in [143]).
Independent of its cause, since all types of replicative
stress generate stalled forks and DSBs, the types of CIN
generated will be very similar. Origin deficiency is likely to
increase the occurrence of under-replicated DNA and
therefore may promote genomic loss. Re-replication specif-
ically promotes amplification, because when two forks
collapse within a re-replication bubble, the structure gener-
ated promotes non-allelic homologous recombination
[121]. It seems that certain regions of the genome show a
higher frequency of amplification in cancer [144] and there
is evidence that chromatin architecture might affect the like-
lihood of re-replication and copy number gain [145].
High throughput sequencing has recently revealed the
extent of CIN, highlighting extensive intrachromosomal
rearrangements and small copy number changes restricted
to subchromosomal regions, termed chromothripsis [146].
Replicative stress, through its preferential targeting of
CFSs, might start to explain this clustering [143]. Break-
induced replicative repair can also help explain the complex
structural rearrangements that are seen. In addition it is
known that micronuclei, initially generated by an aberrant
mitosis, are particularly prone to replicative stress because
they have poor nuclear import of replication and repair fac-
tors. When these under-replicated chromosomes undergocompaction in mitosis, they can incur
multiple DSBs and yet still have the
potential to be incorporated into
the genome, resulting in clustering of
breakpoints [147].
The structural rearrangements
caused by replicative stress can go
onto cause problems in mitosis, when
structurally abnormal chromosomes(usually acentric or dicentric) become misegregated [79]. In
this manner structural chromosomal instability can promote
numerical chromosomal instability. In addition, further
complex chromosomal rearrangements can be generated
by subsequent breakage-fusion-bridge cycles [148].
Although oncogene-induced replicative stress is clearly
important for generating genomic instability early on in
tumorigenesis, other factors such as telomere attrition and
hypoxia are also likely to play significant roles, particularly
at later stages.
Replicative Stress during Cancer Evolution
Even single oncogenes can induce replicative stress by
different mechanisms depending on context. For example,
cyclin E overexpression has been shown to inhibit licensing,
increase origin activation and induce re-replication in
different experiments [3,88,89,100] and Ras promotes both
origin over-usage and re-usage [10]. Thus, it is unlikely that
a single type of replicative stress defines any cancer; in
fact, evidence suggests that the causes of replicative stress
might be quite dynamic during tumorigenesis.
Different mechanisms of replicative stress may also be
more or less important at different stages of tumour evolu-
tion. A vigorous DNA damage response, presumably acti-
vated by replicative stress, can already be seen at one of
the earliest detectable stages of cancer, hyperplasia [3,4].
Levels of pre-RC factors Cdc6 and Cdt1 at this stage,
however, are relatively low [119], suggesting that this replica-
tive stress is unlikely to be due to re-replication. It may be
that, in these earliest stages, replicative stress arises from
reduced origin licensing. Indeed, acute expression of cyclin
E has been shown to reduce licensing and subsequently
reduce DNA synthesis within several hours [88], while ex-
periments which have shown increased origin firing and re-
replication have generally examined cells after several days
of cyclin E overexpression [3,80,89,100]. Re-replication,
and perhaps increased origin firing, probably arises slightly
later during tumour development. This hyperactivity of
origins requires increased transcription of pre-RC factors
through oncogene-induced upregulation of the Rb/E2F
pathway and, in human tumour samples, the pre-RC factors
Cdc6 and Cdt1 only become upregulated from the stage of
Oncogene activation
Increased/deregulated
CDK2 activity
Deregulated p53 and
Rb/E2F pathways
Origin over-usage Origin under-usage Origin re-usage
Reduced licensing
Licensing checkpoint
Increased expression
of licensing factors
Long replication
tracks
Head-to-tail fork
collisions
Dormant origin
activation
Fork stalling/collapse
Enter mitosis with under-
replicated DNA
DNA DSBs
Genomic instability
Replication–
transcription collisions
Replication factor
exhaustion
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Figure 4. Oncogene activation causes repli-
cative stress and genomic instability.
Oncogene activation can interfere with repli-
cation initiation in various ways (orange
boxes) causing origin over-usage, under-
usage or re-usage; the circles on DNA repre-
sent replication origins with green circles
being origins that normally fire during S phase
and red circles denoting dormant origins. This
results in replicative stress (red boxes),
causing fork stalling or collapse which can
lead to DNA damage in S phase or when cells
enter mitosis with under-replicated DNA.
Dashed arrows indicate the ways in which
origin re-usage can cause similar effects to
origin over-usage if re-firing is occurring
frequently. A couple of measures used to
restrict replicative stress are also highlighted
(green boxes). See text for full details.
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R441dysplasia, well after the DDR is first
detected. Moreover, levels of both
Cdc6 and Cdt1 increased further on
progression from dysplasia to carci-
noma, which did not correlate with a
simple increase in proliferation rate
[119]. In addition, the transformation
capability of Cdc6 and Cdt1 overex-
pression is greater if non-primary cells
are used, which are more reflective of
the dysplastic stage [119].
Although replicative stress is a hall-
mark of early tumour progression, and
this can be mimicked by manipulating
levels of replication factors, mutations
in replication factors are rare in cancer (Figure 3A). This is
not surprising when one considers that replicative stress
is actually detrimental to the cell, initially inducing apoptosis
or senescence. Also, although replicative stress specifically
drives genomic instability, which is important for tumour
progression, there is evidence to suggest that primary cells
already have high enough mutation rates to account for the
number of mutations required to transform cells [2]. There-
fore, it seems unlikely that mutations that drive replicative
stress would ever be selected alone. Instead oncogenes,
selected for their ability to promote proliferation, generate
replicative stress as a by-product, due to upregulation of
the Rb/E2F pathway and increased CDK activity, and this
in turn promotes genomic instability. However, replication
factors occasionally become amplified, and this is generally
as part of an oncogene cluster, for example Cdc6 is
frequently amplified with ERBB2 [119], and RecQL4 and
MTBP are frequently co-amplified with Myc (Figure 3B). It
is interesting to consider the possibility that amplification
of some limiting replication factors along with known
oncogenes may increase the fitness of these transformed
cells and thus contribute to oncogenesis.
As mutations in p53 and other DDR factors are selected
in response to oncogene-induced replicative stress, exten-
sive genomic instability develops. The acquisition of further
mutations in oncogenes and tumour suppressor genes
may reduce the tumour’s dependency on replicative stress
as a driving factor for tumour progression. Even so, repli-
cative stress will continue to generate DNA damage andprovide the substrates for selection of novel mutations
contributing to rapid evolution and genetic heterogeneity
in tumours.
Concluding Remarks and Future Perspectives
Evidence suggests that oncogenes deregulate replication
initiation and in turn drive genomic instability via various
mechanisms (Figure 4). Although it now seems likely that
oncogene-induced replicative stress has a role to play in
early progression of many tumours, further work is required
to understand exactly which types of replicative stress
contribute towards DNA damage seen in precancerous le-
sions. The presence of replicative stress in cancer cells has
interesting implications for cancer therapies. It may explain
why certain tumour types stop responding to traditional
genotoxic therapeutics, since replicative stress selects for
mutations that overcome the DDR. In addition, it may open
up new possibilities for therapeutic targets; for example, in
advanced tumours where the DDR has been bypassed, the
remaining active components of the DDR pathway may aid
the tumour in coping with continuing replicative stress by
promoting fork stability and repair. Here, targeting other
genes that constitute the DDR pathway may actually sup-
press tumorigenesis [149,150].
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